Justin Wolf's questions to Y-mAbs Therapeutics Inc (YMAB) leadership • Q2 2024
Question
Justin Wolf from Jones Trading requested more color on the expected timeline for Parts B and C of the SADA clinical study, relative to the progress of Part A.
Answer
President and CEO Michael Rossi projected that Part A will conclude later in 2024, with Part B starting in early 2025. He anticipates Part B could potentially be completed in 2025 or early 2026, noting that trial recruitment has accelerated. Chief Medical Officer Dr. Vignesh Rajah added that this timeline is reasonable but remains dependent on the dosimetry results observed along the way.